Ernest Spitzer

Ernest Spitzer

Auto-generated profile, based on publicly available information

Ernest Spitzer

Cardialysis, Rotterdam, the Netherlands; European Cardiovascular Research Institute, Rotterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in The Lancet
Verified
Journal Article
Closed access
PVPascal Vranckx
Pascal Vranckx
MVMarco Valgimigli
Marco Valgimigli
PJPeter Jüni
Peter Jüni
CHChristian Hamm
Christian Hamm
PSPhilippe Gabriel Steg
Philippe Gabriel Steg
RZRobert Zweiker
Robert Zweiker

3 October 2023 in Circulation
Verified
Journal Article
Closed access
RWRon Waksman
Ron Waksman
MPMohit Pahuja
Mohit Pahuja
SDSean van Diepen
Sean van Diepen
APAlastair G. Proudfoot
Alastair G. Proudfoot
DMDavid Morrow
David Morrow
WAWilliam T. Abraham
William T. Abraham
The Shock Academic Research Consortium is a multi-stakeholder group, including representatives from the US Food and Drug Administration and other government agencies, industry, and payers, convened to develop pragmatic consensus definitions useful for the evaluation of clinical trials enrolling patients with cardiogenic shock, including trials evaluating mechanical circulatory support devices. Several in-person and virtual meetings were convened between 2020 and 2022 to discuss the need for developing the standardized definitions required for evaluation of mechanical circulatory support devices in clinical trials for cardiogenic shock patients. The expert panel identified key concepts and topics by performing literature reviews, including previous clinical trials, while recognizing current challenges and the need to advance evidence-based practice and statistical analysis to support future clinical trials. For each category, a lead (primary) author was assigned to perform a literature search and draft a proposed definition, which was presented to the subgroup. These definitions were further modified after feedback from the expert panel meetings until a consensus was reached. This manuscript summarizes the expert panel recommendations focused on outcome definitions, including efficacy and safety.

1 December 2014 in The Lancet Global Health
Verified
Journal Article
Open access
MRMartina Rothenbühler
Martina Rothenbühler
COCrochan J O'SUllivan
Crochan J O'SUllivan
SSStefan Stortecky
Stefan Stortecky
GSGiulio G Stefanini
Giulio G Stefanini
ESErnest Spitzer
Ernest Spitzer
TPThomas Pilgrim
Thomas Pilgrim
Rheumatic heart disease accounts for up to 250 000 premature deaths every year worldwide and can be regarded as a physical manifestation of poverty and social inequality. We aimed to estimate the prevalence of rheumatic heart disease in endemic countries as assessed by different screening modalities and as a function of age. We searched Medline, Embase, the Latin American and Caribbean System on Health Sciences Information, African Journals Online, and the Cochrane Database of Systematic Reviews for population-based studies published between Jan 1, 1993, and June 30, 2014, that reported on prevalence of rheumatic heart disease among children and adolescents (≥ 5 years to <18 years). We assessed prevalence of clinically silent and clinically manifest rheumatic heart disease in random effects meta-analyses according to screening modality and geographical region. We assessed the association between social inequality and rheumatic heart disease with the Gini coefficient. We used Poisson regression to analyse the effect of age on prevalence of rheumatic heart disease and estimated the incidence of rheumatic heart disease from prevalence data. We included 37 populations in the systematic review and meta-analysis. The pooled prevalence of rheumatic heart disease detected by cardiac auscultation was 2·9 per 1000 people (95% CI 1·7-5·0) and by echocardiography it was 12·9 per 1000 people (8·9-18·6), with substantial heterogeneity between individual reports for both screening modalities (I² = 99·0% and 94·9%, respectively). We noted an association between social inequality expressed by the Gini coefficient and prevalence of rheumatic heart disease (p = 0·0002). The prevalence of clinically silent rheumatic heart disease (21·1 per 1000 people, 95% CI 14·1-31·4) was about seven to eight times higher than that of clinically manifest disease (2·7 per 1000 people, 1·6-4·4). Prevalence progressively increased with advancing age, from 4·7 per 1000 people (95% CI 0·0-11·2) at age 5 years to 21·0 per 1000 people (6·8-35·1) at 16 years. The estimated incidence was 1·6 per 1000 people (0·8-2·3) and remained constant across age categories (range 2·5, 95% CI 1·3-3·7 in 5-year-old children to 1·7, 0·0-5·1 in 15-year-old adolescents). We noted no sex-related differences in prevalence (p = 0·829).

1 December 2016 in American Heart Journal
Verified
Journal Article
Closed access
ESErnest Spitzer
Ernest Spitzer
NMNicolas M. Van Mieghem
Nicolas M. Van Mieghem
PPPhilippe Pibarot
Philippe Pibarot
RHRebecca T Hahn
Rebecca T Hahn
SKSusheel Kodali
Susheel Kodali
MLMartin B. Leon
Martin B. Leon

1 May 2017 in JACC
Verified
Journal Article
Closed access
LGLennart van Gils
Lennart van Gils
MCMarie-Annick Clavel
Marie-Annick Clavel
EVE. Mara Vollema
E. Mara Vollema
RHRebecca T. Hahn
Rebecca T. Hahn
ESErnest Spitzer
Ernest Spitzer
NMNicolas M. Van Mieghem
Nicolas M. Van Mieghem

1 July 2015 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
COCrochan J. O’sUllivan
Crochan J. O’sUllivan
PWPeter Wenaweser
Peter Wenaweser
OCOsman Ceylan
Osman Ceylan
JRJulie Rat-Wirtzler
Julie Rat-Wirtzler
SSStefan Stortecky
Stefan Stortecky
LBLutz Buellesfeld
Lutz Buellesfeld
Background—: Pulmonary hypertension (PH) frequently coexists with severe aortic stenosis, and PH severity has been shown to predict outcomes after transcatheter aortic valve implantation (TAVI). The effect of PH hemodynamic presentation on clinical outcomes after TAVI is unknown. Methods and Results—: Of 606 consecutive patients undergoing TAVI, 433 (71.4%) patients with severe aortic stenosis and a preprocedural right heart catheterization were assessed. Patients were dichotomized according to whether PH was present (mean pulmonary artery pressure, ≥25 mm Hg; n=325) or not (n=108). Patients with PH were further dichotomized by left ventricular end-diastolic pressure into postcapillary (left ventricular end-diastolic pressure, >15 mm Hg; n=269) and precapillary groups (left ventricular end-diastolic pressure, ≤15 mm Hg; n=56). Finally, patients with postcapillary PH were divided into isolated (n=220) and combined (n=49) subgroups according to whether the diastolic pressure difference (diastolic pulmonary artery pressure−left ventricular end-diastolic pressure) was normal (<7 mm Hg) or elevated (≥7 mm Hg). Primary end point was mortality at 1 year. PH was present in 325 of 433 (75%) patients and was predominantly postcapillary (n=269/325; 82%). Compared with baseline, systolic pulmonary artery pressure immediately improved after TAVI in patients with postcapillary combined (57.8±14.1 versus 50.4±17.3 mm Hg; P =0.015) but not in those with precapillary (49.0±12.6 versus 51.6±14.3; P =0.36). When compared with no PH, a higher 1-year mortality rate was observed in both precapillary (hazard ratio, 2.30; 95% confidence interval, 1.02–5.22; P =0.046) and combined (hazard ratio, 3.15; 95% confidence interval, 1.43–6.93; P =0.004) but not isolated PH patients ( P =0.11). After adjustment, combined PH remained a strong predictor of 1-year mortality after TAVI (hazard ratio, 3.28; P =0.005). Conclusions—: Invasive stratification of PH according to hemodynamic presentation predicts acute response to treatment and 1-year mortality after TAVI.